Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

# Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.  **Read the full article:** [CNBC](https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*